Regeneron-Roche Post Encouraging New Data For COVID-19 Antibody Cocktail

Regeneron Pharmaceuticals Inc REGN and Roche Holdings AG RHHBY announced positive data from Phase 2/3 2066 study of Ronapreve (casirivimab and imdevimab) or REGN-COV in hospitalized COVID-19 patients.
Related: WHO Backs Regeneron COVID-19 Antibody Cocktail As It Calls For Equal Access.
The trial met its primary endpoint and showed that REGEN-COV significantly reduced viral load in hospitalized patients within seven days of treatment without mounting their antibody response (seronegative) and required low-flow or no supplemental oxygen.
The full results of the study will be presented at ID Week 2021 today.
In this trial, patients who received REGEN-COV experienced a 36% reduced risk of dying within 29 days of treatment. In patients who were seronegative when they entered the trial, the risk was reduced by 56%.
In a safety analysis involving 2,007 patients (REGEN-COV=1,340, placebo=667) serious adverse events occurred in 21% REGEN-COV patients and 26% placebo patients.
Infusion-related and hypersensitivity reactions were more common among REGEN-COV patients (2% and 1% respectively) than placebo patients (1% and less than 0.5%, respectively).
The study also reported results supportive of the much larger UK RECOVERY trial in hospitalized patients.
It showed that patients who received Ronapreve (2,400 mg or 8,000 mg) along with standard care experienced numeric improvements across all clinical endpoints assessed, compared to standard care alone.
Comparable clinical outcomes were recorded with both 2,400 mg and 8,000 mg doses. No new safety signals were identified.
Read Next: FDA Approves Regeneron - Roche's COVID-19 Antibody Cocktail For Post-Exposure Prophylaxis.
Price Action: REGN stock closed at $606.70 on Wednesday.

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga